A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer

Peer Review reports

Original Submission
11 Nov 2022	Submitted	Original manuscript
20 Nov 2022	Reviewed	Reviewer Report - Matthias Briel
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
3 Dec 2022	Editorially accepted
24 Dec 2022	Article published	10.1186/s13063-022-06988-1

Back to article page